Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancer

(MedPage Today) -- Lorlatinib (Lorbrena) topped an older first-line standard for patients with non-small cell lung cancer (NSCLC) and ALK rearrangements, an interim analysis of the international, randomized CROWN trial showed.
Compared with crizotinib...